A Phase I Clinical Study of BBI608 in Adult Patients with Advanced Solid Tumors
Phase 1
- Conditions
- Advanced solid tumors
- Registration Number
- JPRN-jRCT2080222106
- Lead Sponsor
- Sumitomo Dainippon Pharma Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
- Signed, written informed consent
- Patients with histologically or cytologically confirmed solid tumor
- Patients of ECOG performance status of 0 or 1
etc.
Exclusion Criteria
- Patients with any known untreated brain metastases
etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Safety<br>- Pharmacokinetics<br><br>CTCAE (ver.4.0)
- Secondary Outcome Measures
Name Time Method - Efficacy<br>RECIST (ver.1.1)